PUBLISHER: Greystone Research Associates | PRODUCT CODE: 1178747
PUBLISHER: Greystone Research Associates | PRODUCT CODE: 1178747
“Prefillable Biological Drug Delivery Systems to 2028 ” is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this growing segment of the drug delivery sector. The report has been designed and developed to provide pharmaceutical company decision makers, drug developers and formulators, drug device designers, and industry strategists with a detailed understanding of the expanding impact of biological drug self-care on pharmaceutical strategies and healthcare treatment protocols. Provider organization business managers, healthcare administrators and investors will also benefit from this publication.
Specialty prefilled injection devices - a group that includes pen injectors and autoinjectors - are creating new opportunities for drug developers and marketers. These devices provide the ability to create product differentiation in the age of direct-to-consumer marketing.
Because biological drugs most often target chronic conditions, dosing strategies and treatment protocols must be developed for long-term use, often for self-administration by patients who may have limitations directly related to their condition. The shift in as-supplied packaging from single and multi-use vials to prefilled injection devices will accelerate over the next five years as drug developers move to empower an increasing number of chronically ill patients. The powerful physiological effects of antibodies, hormones and other biological drugs also increase the need for safety and compliance.